Giving Dantrium (dantrolene) through the nose rather than by mouth may maximize its neuroprotective properties in treating conditions like Alzheimer’s disease, a new study suggests. The study, “Intranasal administration of dantrolene increased brain concentration and duration,” was published in the journal Plos One. Dantrium, produced by Par Sterile Products, is approved by the U.S. Food and Drug…
This post was originally published on this site “I wish we could put up some of the Christmas spirit in jars and open a jar of it every month.” —Harlan Miller For many people, Christmas is the most wonderful time of the year. The hustle and bustle of shopping for the perfect present, the ringing…
This post was originally published on this site In awarding more than $100 million to support scientific efforts to prevent, slow or reverse Alzheimer’s disease, the nonprofit Cure Alzheimer’s Fund has reached a significant milestone. Since its founding, the 15-year-old organization has backed some 425 novel projects conducted by 170 investigators worldwide. Those projects have resulted…
This post was originally published on this site Troriluzole, an investigational oral therapy by Biohaven, shows a potential to improve cognition and lessen brain volume loss, a sign of Alzheimer’s disease progression, a board reviewing the ongoing Phase 2/3 trial decided. The trial successfully completed its interim futility analysis — meaning it can efficiently reach preset…
This post was originally published on this site With its annual essay competition, the Alzheimer’s Foundation of America (AFA) is again offering high schoolers affected by Alzheimer’s disease a chance to motivate others and earn money for college. In the AFA Teens for Alzheimer’s Awareness College Scholarship Essay Contest, college-bound high school seniors nationwide are invited…
This post was originally published on this site [Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse —…
This post was originally published on this site A record number of people are expected to travel this holiday season. The travelers will undoubtedly include familial caregivers journeying with loved ones who have dementia. These are courageous individuals, perhaps seeking one last hurrah before Alzheimer’s disease prevents them from traveling to faraway destinations. Taking a…
This post was originally published on this site A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics and…
This post was originally published on this site Researchers at Maastricht University Medical Center in the Netherlands have developed two online apps to improve the lives of people who care for dementia patients, and will soon create one for patients themselves. One app provides caregivers with information they can use to achieve balance in their lives. Those…
This post was originally published on this site People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse — a worsening of delusions and hallucinations — than others, HARMONY trial data show. HARMONY met its main goal, significantly lowering the…
